Regulation of ferritin: a specific role for interferon-alpha (IFN-alpha)? The acute phase response in patients treated with IFN-alpha-2b

Eur J Clin Invest. 2002 Mar:32 Suppl 1:79-83. doi: 10.1046/j.1365-2362.2002.0320s1079.x.

Abstract

Background: Adult onset of Still's disease is characterized by very high serum ferritin levels, in disproportion with other acute phase proteins (APPs). Because interferon-alpha (IFN-alpha) was observed to cause hyperferritinaemia in three healthy people without increase of other APPs, we hypothesized that IFN-alpha stimulates specifically the synthesis of ferritin. To test this hypothesis, we studied ferritin and other APP levels in patients treated with IFN-alpha.

Patients and methods: Fifteen patients treated with IFN-alpha-2b 3-5 times a week, as adjuvant treatment after excision of a high-risk melanoma, were compared with six patients without adjuvant treatment (controls). Serum levels of C-reactive protein (CRP) and secretory phospholipase A2 (sPLA2) were measured using ELISA. Levels of ferritin, alpha1-acid glycoprotein (AAG) and albumin were determined by nephelometry.

Results: CRP was decreased significantly after 4 weeks (P < 0.01) in the patients treated with IFN-alpha compared with the nontreated patients, after 6 months of treatment it was still decreased although not significantly. Ferritin increased significantly in the IFN-alpha-treated patients: 187% of pretreatment value after 4 weeks and 217% after 6 months (P < 0.01), while ferritin levels decreased in the nontreated patients. AAG increased significantly in IFN-alpha-treated patients (107, 114%) compared with the control-patients (91, 76%) but differences were less compared with CRP and ferritin. sPLA2 had a variable course, while albumin remained constant within the normal range in both patient groups.

Conclusions: IFN-alpha induced a significant increase in ferritin, with a significant decrease in CRP, little increase in AAG, varying response of sPLA2 and no change in albumin. This finding suggests a specific role for IFN-alpha in the synthesis or secretion of ferritin. This mechanism may also be involved in the marked hyperferritinaemia in adult onset of Still's disease.

Publication types

  • Clinical Trial

MeSH terms

  • Acute-Phase Reaction / immunology
  • Acute-Phase Reaction / metabolism
  • Adult
  • Aged
  • Antineoplastic Agents / administration & dosage*
  • C-Reactive Protein / metabolism
  • Female
  • Ferritins / blood
  • Ferritins / immunology*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage*
  • Interferon-alpha / immunology*
  • Interferon-alpha / metabolism
  • Male
  • Melanoma / drug therapy
  • Middle Aged
  • Phospholipases A / blood
  • Phospholipases A2
  • Recombinant Proteins
  • Skin Neoplasms / drug therapy
  • Still's Disease, Adult-Onset / blood
  • Still's Disease, Adult-Onset / drug therapy*
  • Still's Disease, Adult-Onset / immunology*

Substances

  • Antineoplastic Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • C-Reactive Protein
  • Ferritins
  • Phospholipases A
  • Phospholipases A2